Cisco Systems: profit locked in, signal fading
Cisco is at week 8 of a buy trade that has already delivered 40% profit. All 3 targets of our most advanced model have been hit, but the management roadmap runs to week 10. The stop is now at breakeven: risk is zeroed out.
AXA SA: sell signal unconfirmed as technical rebound takes hold
Four weeks into the sell signal on AXA SA, the market replies with a sharp rebound: +3.4% in the latest weekly session, buy volume at 88%. The downside has never confirmed, and the quality band flags trading as not recommended.
CoreWeave: sell signal is in, but the risk is high
CoreWeave enters its first week under a sell signal. Setup quality is ordinary and the structure is bearish, but the stock remains above the 200-week average: our model flags trading as not recommended.
CrowdStrike: +52% from entry, model eyes the week-8 window
CrowdStrike is at week 7 of a buy signal with a 52% gain from entry. All 3 model statistical references have been hit ahead of schedule. The next management window falls at week 8.
CRISPR Therapeutics at Week 8: tight dynamic stop, weak confirmation
CRISPR Therapeutics is at week 8 of a buy signal, down 14%. The confirmation week closed bearish: the model flags exit. The dynamic stop is nearly at entry level.
Salesforce: negative confirmation, the model flags an exit
Buy signal on Salesforce at week 1, but the confirmation week closed bearish: the model flags an exit. Elevated volatility and a dynamic stop at -2.40% from entry for those staying in.